Full Breakdown
FDA Refuses to Review Moderna's mRNA Flu Vaccine Application
2/13/2026, 7:20:19 AM
Overview of the FDA's Decision
The U.S. Food and Drug Administration (FDA) has declined to review Moderna's application for its mRNA-based flu vaccine, mRNA-1010, citing concerns over the adequacy of the clinical trial design. The refusal-to-file letter, issued by Dr. Vinay Prasad, the director of the FDA's Center for Biologics Evaluation and Research (CBER), stated that the study did not use a comparator that reflects the "best-available standard of care" for older adults, specifically those aged 65 and over. This decision has raised significant concerns within the biopharmaceutical industry regarding the regulatory landscape for mRNA vaccines.
Details of the Clinical Trials
Moderna's application was based on two Phase 3 trials involving over 40,000 participants, which compared the mRNA vaccine to GSK's Fluarix, a standard-dose flu vaccine. The FDA's letter indicated that this choice of comparator was inadequate, as it did not align with the CDC's recommendations for high-dose vaccines for seniors, which are believed to provide better protection. Despite this, Moderna argued that the FDA had previously approved the trial design and that the application met all regulatory requirements.
Official Statements & Responses
Moderna's CEO, Stéphane Bancel, expressed disappointment, stating, "It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator." The company has requested a Type A meeting with the FDA to clarify the path forward. Meanwhile, Andrew Nixon, a spokesperson for the Department of Health and Human Services (HHS), defended the FDA's decision, asserting that Moderna's trial exposed older participants to increased risks by using a substandard comparator.
Criticism & Opposition
The FDA's decision has drawn criticism from various quarters, including health experts who argue that the refusal could stifle innovation in vaccine development. Dr. Seth Berkley, a senior advisor at the Brown University Pandemic Center, noted that the refusal could deter companies from investing in vaccine research if they anticipate regulatory hurdles. Critics also point to the broader implications of the decision, suggesting it reflects a shift in U.S. health policy under HHS Secretary Robert F. Kennedy Jr., who has been skeptical of mRNA technology.
Conflicting Reports & Gaps
There are conflicting accounts regarding the FDA's rationale for rejecting the application. While the FDA emphasized the inadequacy of the comparator used in the trials, Moderna maintains that it followed all prior guidance from the agency. The refusal-to-file letter did not cite any safety or efficacy concerns regarding the vaccine itself, which has led to questions about the consistency of the FDA's regulatory framework.
What's Next for Moderna?
Moderna's mRNA flu vaccine remains under review in other countries, including Canada, Australia, and the European Union. The company is expected to continue its efforts to engage with the FDA to seek clarity on the regulatory process and potentially resubmit its application with revised trial data. The outcome of this situation could have significant implications for the future of mRNA technology in vaccine development, particularly as the company navigates a changing regulatory environment.
Verbatim Quotes
- “It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting.” — Stéphane Bancel, CEO of Moderna
- “The FDA rejected Moderna’s application for filing because the company refused to follow very clear FDA guidance from 2024 to test its product in a clinical trial against a CDC-recommended flu vaccine to compare safety and efficacy,” — Andrew Nixon, HHS Spokesperson
- “This is a very worrisome event which does not bode well for ’standard’ operations and decision making within FDA,” — Dr. Wilbur Chen, Infectious Disease Physician
The FDA's refusal to review Moderna's application for its mRNA flu vaccine underscores the complexities and challenges facing vaccine developers in the current regulatory climate, particularly as public health policies evolve under new leadership.
